Nanodelivery Strategies for STING Agonists: Toward Efficient Cancer Immunotherapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• The cyclic GMP-AMP synthetase-interferon gene stimulator (cGAS-STING) signaling pathway shows promise in cancer treatment.
• Direct delivery of STING agonists faces challenges including degradation, low bioavailability, and systemic side effects, limiting their use, especially for metastatic cancers.

Purpose of the Study:

• To explore the synergy between nanodelivery systems and the STING signaling pathway for enhanced cancer therapy.
• To systematically review STING agonists, nanocarrier types, and delivery strategies for improved cancer treatment.

Main Methods:

• Comprehensive review of existing STING agonists and nanodelivery systems.
• Analysis of delivery strategies focusing on tumor microenvironment (TME), tumor cell targeting, and multifunctional systems.
• Evaluation of novel biomaterials for STING agonist delivery.

Main Results:

• Nanocarriers can overcome limitations of standalone STING agonists, improving bioavailability and enabling broader application.
• Delivery strategies involving TME modulation, targeted delivery, and integrated systems show potential for enhanced efficacy.
• Novel biomaterials offer new avenues for developing advanced STING nanodelivery systems.

Conclusions:

• Nanodelivery systems offer a promising strategy to enhance the therapeutic potential of STING agonists in cancer.
• Further research into advanced delivery strategies and biomaterials is crucial for optimizing STING-based cancer therapies and addressing current challenges.